

Resource Summary Report

Generated by [NIF](#) on Aug 22, 2026

[Crl:CD1-Foxn1^{NU}](#)

RRID:IMSR_CRL:086

Type: Organism

Proper Citation

RRID:IMSR_CRL:086

Organism Information

URL: <http://www.criver.com/products-services/basic-research/find-a-model/cd-1-nude-mouse>

Proper Citation: RRID:IMSR_CRL:086

Description: Mus musculus with name Crl:CD1-Foxn1^{NU} from IMSR.

Species: Mus musculus

Notes: gene symbol note: ; inbred strain:

Catalog Number: CRL:086

Database: Charles River Laboratories

Database Abbreviation: CRL

Availability: live

Organism Name: Crl:CD1-Foxn1^{NU}

Record Creation Time: 20250513T062409+0000

Record Last Update: 20260815T055928+0000

Ratings and Alerts

No rating or validation information has been found for Crl:CD1-Foxn1^{NU}.

No alerts have been found for Crl:CD1-Foxn1^{NU}.

Data and Source Information

Source: [Integrated Animals](#)

Source Database: Charles River Laboratories

Usage and Citation Metrics

We found 352 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#).

Peng R, et al. (2026) Targeting the MAPK/ERK signaling pathway: Mechanistic analysis of pexidartinib in overcoming adriamycin resistance in breast cancer. *Experimental cell research*, 462(1), 115127.

Hyle J, et al. (2026) Deciphering resistance mechanisms to auxin-inducible protein degradation in mammalian cells. *The Journal of biological chemistry*, 302(7), 113232.

Malone HA, et al. (2026) PHIP suppresses NuRD to enable the growth of SWI/SNF-mutant cancers. *Nature communications*, 17(1).

Valentini E, et al. (2026) PROTAC-mediated degradation of Bcl-xL potentiates target therapy in preclinical melanoma models. *Journal of experimental & clinical cancer research* : CR, 45(1), 37.

Panico S, et al. (2026) Prolyl 3-Hydroxylase 2 Supports a Pro-Angiogenic Milieu Promoting Colorectal Cancer Progression and Metastasis. *International journal of molecular sciences*, 27(4).

Sulava S, et al. (2026) Therapeutic profiling of dihydroartemisinin using in vitro and in vivo models reveals anti-glioma potential. *Cancer cell international*, 26(1).

Vallatos A, et al. (2026) Marginal diffusion slope as a prognostic imaging biomarker of infiltrating phenotype in glioblastoma; A cancer imaging biomarker roadmap study. *Neuro-oncology advances*, 8(1), vdag028.

Sekar A, et al. (2026) TMPRSS2-ERG confers resistance of prostate cancer to antiandrogens. *EMBO molecular medicine*, 18(6), 2062.

Vaccarin C, et al. (2026) Optimizing uPAR-targeting radiopeptides for improved tissue distribution: progress towards radionuclide therapy. *European journal of nuclear medicine and molecular imaging*, 53(4), 2502.

Wendlinger L, et al. (2026) Novel radiohybrid PET-Tracers for SST2-targeted imaging of neuroendocrine tumors. *European journal of nuclear medicine and molecular imaging*, 53(4), 2518.

Dalleywater W, et al. (2026) Generation of biologically responsive colon-like intestinal tissue patches from human induced pluripotent stem cells using a rapid co-differentiation platform. *Stem cell research & therapy*, 17(1).

Williams JS, et al. (2026) Patient-derived pediatric brain tumor orthotopic xenografts and tumor organoids faithfully recapitulate primary tumors. *Science advances*, 12(16), eaea4966.

Wallimann RH, et al. (2025) Preclinical comparison of (radio)lanthanides using mass spectrometry and nuclear imaging techniques: biodistribution of lanthanide-based tumor-targeting agents and lanthanides in ionic form. *European journal of nuclear medicine and molecular imaging*, 52(4), 1370.

Cammareri P, et al. (2025) Loss of colonic fidelity enables multilineage plasticity and metastasis. *Nature*, 644(8076), 547.

Han Y, et al. (2025) TGF- β 1-based restoration of sodium iodide symporter expression in radioiodine-refractory differentiated thyroid cancer via engineered MSCs. *Molecular therapy : the journal of the American Society of Gene Therapy*, 33(12), 6130.

Alshuhri MS, et al. (2025) MRI Delta Radiomics to Track Early Changes in Tumor Following Radiation: Application in Glioblastoma Mouse Model. *Biomedicines*, 13(4).

Sarkar S, et al. (2025) A biorthogonal chemistry approach for high-contrast antibody imaging of lymphoma at early time points. *EJNMMI research*, 15(1), 26.

Roulstone V, et al. (2025) Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion. *Nature communications*, 16(1), 4855.

Ramírez-Ruiz F, et al. (2025) Polycaprolactone for Hard Tissue Regeneration: Scaffold Design and In Vivo Implications. *Bioengineering (Basel, Switzerland)*, 12(1).

Carrieri L, et al. (2025) Proteoglycan-4 potentiates the antitumor efficacy of regorafenib in an orthotopic model of hepatocellular carcinoma. *Journal of experimental & clinical cancer research : CR*, 45(1), 7.